A few known aspect about cancer is that genetic alterations are not inherent, in the majority of cases, of a specific kind of tumor, but they are shared in some types of tumors from a different origin. New advances on molecular biology have made it possible to asses that primary brain tumors , pancreatic cancers and lung cancers have very relevant genetic alterations which are the same for the three types of cancer. First objective of our investigative group is the identification and correct treatment of this new kind of cancers which is due to the existence of the EGFR gene mutation and has got a specific treatment. Second objective is the customized treatment of advanced lung cancer , giving individualized chemotherapy according to BRCA1 levels. Third objective is to customize postoperative chemotherapy in the chirurgic patients that, although having had a satisfactory operation, have high risk of recurrence because of lymph node affectation. Finally, long term objectives lie in the modernization of the oncology, being understood in a global way , since cancer is a genetic illness and we understand that modern oncologist , from now on, will be able to treat in a more convenient way and from the same perspective , tumors from different origins with selective medical treatments for specific tumors of a different origin which are dependent or subclasses of the mentioned genetic alterations.